| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Department of Pathology, Jichi Medical School, Tochigi, Japan
| Abstract |
|---|
|
|
|---|
-smooth muscle actin
(
-SMA) or S100 protein. By double-fluorescence immunostaining of the
tunica muscularis of the GI tract wall, co-expression of
KIT, CD34, and SMemb was demonstrated in ICCs,
which were negative for SM1 and SM2. RT-PCR analysis confirmed that
GIST expressed SMemb-mRNA, which lacked neuronal cell-specific
inserts of 30 bp. These facts further strengthen the current hypothesis
that GIST is a tumor of ICCs.
| Introduction |
|---|
|
|
|---|
In an attempt to characterize neoplastic cells of GIST, in the present study we evaluated the expression profile of myosin heavy chain (MHC) isoforms SM1, SM2, and the embryonic form (SMemb). SM1 and SM2 are alternatively spliced products of a single gene.10,11 Both are specific to SMCs but are regulated differently in fetal development. SM1 is expressed in SMCs throughout the early developmental stage to the mature stage, whereas SM2 is expressed only after birth.11,12 SMemb is referred to as the nonmuscle MHC isoform and is a product of a different gene. In addition to its abundance in the brain, SMemb is expressed together with SM1 in SMCs undergoing growth and/or cell division, such as embryonic SMCs of fetal aorta and proliferating SMCs in arteriosclerotic neointima.12,13 In the present study, we demonstrated that the profile of MHC isoforms in neoplastic cells of GIST was different from that in both mature and developing SMCs, but the same as that in ICCs, thus providing further evidence that GIST is a tumor of interstitial cells of Cajal (TICC).
| Materials and Methods |
|---|
|
|
|---|
Twenty-seven GISTs were surgically resected from 26 patients (age, 33 to 80 years; 10 male and 16 female). These tumors consisted of 24 primary tumors of 23 patients and 3 metastatic tumors of 3 patients. These tumors were examined in our previous study, and the clinicopathological details have been reported.14 The sites of the primary tumors were the stomach (n = 18), duodenum (n = 2), jejunum (n = 1), ileum (n = 1), and colon (n = 2). The three metastatic tumors, for which primary tumors were not available, were derived from GISTs of the stomach, duodenum, and rectum, respectively. Formalin-fixed and paraffin-embedded specimens were used for histopathological and immunohistochemical studies. As a control, nine leiomyomas (three of the uterus and six of the esophagus), eight leiomyosarcomas of the uterus, and three Schwannomas of the retroperitoneum and mediastinum were similarly examined. All of the GISTs were histologically classified as high or low risk according to the criteria of Franquemont with some modifications as have been previously reported.14
Non-Neoplastic Tissue
For the immunohistochemical study of ICCs, non-neoplastic tissues of the human stomach, small intestine, and colon, which were surgically resected, were fixed in acetone at -20°C overnight and then rinsed in methyl benzoate and xylene and embedded in paraffin (AMeX method),15 as long cytoplasmic processes of ICCs were lost by routine formalin fixation. Fifteen-micron-thick sections were used for the visualization of long and slender dendrites of ICCs.
Immunohistochemical Study
Immunohistochemical evaluation was performed using the
avidin-biotin-peroxidase complex (ABC) method in 3-µm-thick sections
of formalin-fixed and paraffin-embedded specimens of GISTs and other
mesenchymal tumors. Monoclonal antibodies against MHC isoforms SM1, SM2
and SMemb were purchased from YAMASA (Tokyo, Japan) and used at a
working dilution of 1:6000. A polyclonal antibody for KIT was obtained
from MBL (Nagoya, Japan), and a monoclonal antibody for CD34 was
obtained from Becton Dickinson (Mountain View, CA). The working
dilution was 1:100 and 1:20, respectively. Cellular differentiation in
GISTs was partially characterized in a previous study13
using the following antibodies:
-SMA (DAKO, Kyoto, Japan;
monoclonal, working dilution, 1:500) as a marker for SMCs and S100
protein (DAKO; polyclonal, 1:1000) as a marker for neuronal cells.
Ki-67 (MBL; monoclonal, 1:100) was used to assess the proportion of
proliferating cells, and a Ki-67 labeling ratio was estimated as
reported previously. To recover the antigenicity of Ki-67, SM1, SM2,
and SMemb, formalin-fixed sections were pretreated in a microwave oven
before incubation with the primary antibody.
Fluorescence Double Immunolabeling
Fluorescence double immunostaining was performed using combinations of rabbit polyclonal anti-KIT antibody with other mouse monoclonal antibodies (S100ß (IBL, Fujioka, Japan; monoclonal, 1:100), CD34, SM1, SM2, and SMemb). After incubation with the combination of primary antibodies for 1 hour at room temperature, the sections were thoroughly washed with phosphate-buffered saline. They were then incubated with tetramethylrhodamine isomer R (TRITC)-conjugated swine anti-rabbit IgG (DAKO; 1:40) and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (American Qualex, San Clemente, CA; 1:40) for 30 minutes at room temperature. The sections were examined with a confocal laser scanning microscope (Leica TCS NT). The excitation wavelength was 568 nm for TRITC and 488 nm for FITC.
Transcriptional Analysis of SMemb
Transcriptional expression of SMemb was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) analysis using the tumor RNA of GISTs (n = 3), leiomyomas of the uterus (n = 3), and Schwannomas (n = 3, with 2 arising from retroperitoneum and 1 from mediastinum), as well as the adult brain, which is known to contain a large amount of SMemb. All three of the tumor tissues of GISTs showed immunoreactivity for SMemb. All of the tissues had been taken immediately after resection, frozen in dry ice/hexane, and stored at -80°C until use. Total RNA was prepared from frozen tissues with TRIZOL Reagent (GIBCO BRL, Rockville, MD) according to the manufacturer's recommendations. Two micrograms of total RNA from each sample was reverse-transcribed to cDNA using a first-strand cDNA synthesis kit (Pharmacia Biotech, Tokyo, Japan). The resulting cDNA was then used for PCR amplification with the upstream primers (5'-AGGAAGAAAGGACCATAATATTCC-3') and the downstream primers (5'-CCTGTAGTTATTAAATCCTTCAAG-3'). The primers were set up to amplify the fragment of SMemb mRNA encompassing the N30 exon, a 30-nucleotide insert in a splicing variant, which has been reported to be specific for the brain, retina, and retinoblastoma cell line.16-18 After acrylamide gel electrophoresis, the gel was stained with ethidium bromide. The amplified fragments were excised from the gels and used to determine the nucleotide sequences of the amplified fragments with an ABI PRISM D-rhodamine terminator cycle sequencing ready reaction kit (Applied Biosystem, Chiba, Japan) and an ABI PRISM 377 DNA sequencer.
Statistical Analysis
Fisher's exact probability test, the Kruskal-Wallis rank test, and Student's t-test were used for the statistical analysis.
| Results |
|---|
|
|
|---|
|
Immunohistochemically, SM1 and SM2 were definitely present in SMCs
of tunica muscularis (Figure 1a)
but
completely absent in GISTs (Figure 1c)
, except for one GIST in which
several neoplastic cells showed weak positive staining. Both isoforms
were present in all of the leiomyomas and in five of eight
leiomyosarcomas but not in any of the Schwannomas. On the other hand,
although SMemb immunoreactivity was completely negative in SMCs of the
tunica muscularis (Figure 1b)
, SMemb immunoreactivity was observed in
neoplastic cells in 18 of 27 GISTs (67%; Figure 1d
). SMemb
immunoreactivity was not demonstrated in tumor cells of leiomyomas or
Schwannomas except for the SMCs of small vessels in the capsule of one
of the Schwannomas. In two of the eight leiomyosarcomas, several
neoplastic cells were weakly positive for SMemb, but these neoplastic
cells were also immunoreactive for SM1 and SM2.
|
-SMA immunoreactivity was observed in 10 of 27 GISTs (37%), in
contrast to 9 of 9 leiomyomas and 4 of 8 leiomyosarcomas. The
-SMA
immunoreactivity in GISTs was weak compared with that in leiomyomatous
tumors and was confined in a focal area. Only one case of GIST showed
positivity for S-100 protein.
As for the correlation between SMemb expression and pathological
factors or cellular differentiation in GIST (Table 2)
, SMemb expression was not correlated
with sex, age, size, histological grade, or the Ki-67 labeling ratio.
There was an intimate correlation between the expression of SMemb and
KIT (P < 0.05), whereas there was no
significant correlation between SMemb and
-SMA, CD34, or S100
protein. The expressions of KIT and CD34 were also closely correlated
(P < 0.05).
|
To identify the cells corresponding to ICCs, we used KIT immunohistochemistry because of the feasibility of a polyclonal antibody. As KIT-immunoreactive cells do not always represent ICCs, the immunoreactive interstitial cells or the cells with similar morphology, which were apparently different from mast cells, were described as ICC-like cells in the present study.
In the stomach and colon, KIT-immunoreactive ICC-like cells were
distributed widely in both inner circular and outer longitudinal muscle
layers of the tunica muscularis. The immunoreactive cells were fusiform
or stellate in shape with long cytoplasmic processes, and formed a
complex cell network (Figure 2a)
. By
double immunostaining, most of the KIT-immunoreactive cells were also
positive for CD34, but some fusiform and stellate ICC-like cells were
positive for CD34 and negative for KIT (Figure 2b
, green fluorescence),
and some KIT-positive ICC-like cells were negative for CD34 (Figure 2c
,
red). There seemed to be no difference in the morphology or
location among these KIT(+)CD34(+), KIT(+)CD34(-), and KIT(-)CD34(+)
ICC-like cells in the tunica muscularis. KIT-immunoreactive ICC-like
cells (Figure 2e
, red) were definitely positive for SMemb (Figure 2d
,
green; Figure 2f
, yellow). These KIT-immunoreactive cells were
completely negative for S100-ß, SM1, and SM2.
|
As an internal control for immunohistochemistry, the SMCs of the tunica muscularis were completely negative for KIT, SMemb, CD34, and S-100ß protein but definitely positive for SM1 and SM2. Ganglion cells in the Auerbach plexus were negative for these antibodies.
Transcriptional Analysis of SMemb
By RT-PCR analysis of SMemb mRNA, two distinct fragments were
amplified in human adult brain tissue, which corresponded to
transcripts with (346 bp) or without the N30 insert (316 bp). The DNA
sequence of the excised fragments confirmed the specificity of the
amplification. On the other hand, only a single fragment of 316 bp,
corresponding to SMemb devoid of the N30 insert, was amplified in
three of three GISTs. Similarly, a single fragment of 316 bp was barely
amplified in each of three leiomyomas and Schwannomas (Figure 3)
. With regard to immunohistochemistry,
these faint fragments might correspond to the SMemb in small vessels
feeding the tumors.
|
| Discussion |
|---|
|
|
|---|
-SMA, which is another marker protein for smooth muscle
differentiation. These immunohistochemical findings were apparently
different from those in leiomyoma and leiomyosarcoma, confirming that
GIST is distinct from a genuine leiomyomatous neoplasm. Although SMemb
mRNA in neuronal cells includes a specific 30-nucleotide insert by
alternative splicing,17,18
RT-PCR analysis of GIST mRNA
demonstrated amplification of only a single fragment of SMemb
transcript that lacked this insert. Therefore, if SMemb expression in
the neoplastic cells of GISTs reflects the characteristics of a
normal counterpart, the candidate should be cells other than SMCs and
neuronal cells. Based on the current hypothesis that GIST may be a tumor of ICCs,6,7 we investigated SMemb expression in ICCs. Although Cajal originally considered the cells as neuronal cells, recent reports suggest that ICCs may be derived from a mesenchymal cell; ICCs can be induced in fetal GI tract by the expression of Sonic hedgehog (Shh).20 Transcripts of both c-kit and smooth muscle myosin heavy chain genes were demonstrated in mesenchymal progenitor cells of the GI tract in the mouse embryo.21 In the present study, KIT-positive ICC-like cells in the muscular layer of the stomach and the colon were definitely positive for SMemb by fluorescence double immunolabeling. Moreover, most of the double-positive cells also showed immunoreactivity for CD34 antigen. These findings parallel those in GIST, providing additional evidence that GIST is a tumor of ICCs (TICC) in the GI tract. Two leiomyosarcomas showed SMemb, but neoplastic cells were also immunoreactive for SM1 and SM2, suggesting that the expression of SMemb may be caused by dedifferentiation or dysregulation of MHC isoforms in these highly malignant leiomyomatous tumors.
The exact function of SMemb is still under study, but it has been reported that SMemb is expressed in large amounts in human brain17,18 and is considered to play an important role in axon formation and the direction of outgrowth in neurons, by generating tension between growth cones or bundling of actin filaments.22 On the other hand, ICCs have long cytoplasmic processes, like axons, and form a complex network in lamina muscularis.23 Moreover, ICCs show an impulse conductive function, and slow-wave peristalsis is blocked in W/Wv mouse or Ws/Ws rat, in which ICCs are absent because of a loss-of-function mutation of the c-kit gene.24,25 Thus, based on the correspondence of morphology and function in the two types of cells, SMemb may play a role in the formation and preservation of dendrites and the cell network of ICCs, although the neuron-specific N30 insert variant of SMemb was not present in GISTs.
It is worth noting that KIT(+)SMemb(+) ICC-like cells in the small intestine were negative for CD34. As most of the corresponding cells in the stomach and colon were immunoreactive for CD34, the finding may indicate that ICCs in the human GI tract may be heterogeneous with regard to phenotype.24,27 It is possible that this variable phenotype is linked to the variable function of ICCs as other than the pacemaker of the GI tract. In this context, the term gastrointestinal pacemaker cell tumor (GIPACT), which was recently proposed by Kindblom et al as a substitute for GIST,7 does not seem to be appropriate.
In conclusion, the concomitant expression of SMemb with KIT and CD34 was observed in both GISTs and ICCs. The findings in the present study further strengthen the current hypothesis that most GISTs are tumors of ICCs (TICCs) in the GI tract, although the functional significance of SMemb in ICCs and its related tumor, TICC, requires further clarification.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.
Accepted for publication September 22, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. L. Corless, J. A. Fletcher, and M. C. Heinrich Biology of Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-E. Andersson and A. Arner Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology Physiol Rev, July 1, 2004; 84(3): 935 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Antonescu, A. Viale, L. Sarran, S. J. Tschernyavsky, M. Gonen, N. H. Segal, R. G. Maki, N. D. Socci, R. P. DeMatteo, and P. Besmer Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site Clin. Cancer Res., May 15, 2004; 10(10): 3282 - 3290. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rosai GIST: An Update International Journal of Surgical Pathology, July 1, 2003; 11(3): 177 - 186. [PDF] |
||||
![]() |
F. Del Piero, B. A. Summers, J. F. Cummings, G. Mandelli, and E. A. Blomme Gastrointestinal Stromal Tumors in Equids Vet. Pathol., November 1, 2001; 38(6): 689 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Rubin, S. Singer, C. Tsao, A. Duensing, M. L. Lux, R. Ruiz, M. K. Hibbard, C.-J. Chen, S. Xiao, D. A. Tuveson, et al. KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors Cancer Res., November 1, 2001; 61(22): 8118 - 8121. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsujimura, C. Makiishi-Shimobayashi, J. Lundkvist, U. Lendahl, K. Nakasho, A. Sugihara, T. Iwasaki, M. Mano, N. Yamada, K. Yamashita, et al. Expression of the Intermediate Filament Nestin in Gastrointestinal Stromal Tumors and Interstitial Cells of Cajal Am. J. Pathol., March 1, 2001; 158(3): 817 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Crosby, C. N. Catton, A. Davis, J. Couture, B. O'Sullivan, R. Kandel, and C. J. Swallow Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database Ann. Surg. Oncol., January 1, 2001; 8(1): 50 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. C. Plaat, H. Hollema, W. M. Molenaar, G. H. T. Broers, J. Pijpe, M. F. Mastik, H. J. Hoekstra, E. van den Berg, R. J. Scheper, and W. T. A. van der Graaf Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins J. Clin. Oncol., September 18, 2000; 18(18): 3211 - 3220. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Robinson, K. Sircar, B. R. Hewlett, K. Chorneyko, R. H. Riddell, and J. D. Huizinga Gastrointestinal Stromal Tumors May Originate from a Subset of CD34-Positive Interstitial Cells of Cajal Am. J. Pathol., April 1, 2000; 156(4): 1157 - 1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Rubin, J. A. Fletcher, and C. D. M. Fletcher Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors International Journal of Surgical Pathology, January 1, 2000; 8(1): 5 - 10. [Abstract] [PDF] |
||||
![]() |
Y. Natkunam, R. V. Rouse, S. Zhu, C. Fisher, and M. van de Rijn Immunoblot Analysis of CD34 Expression in Histologically Diverse Neoplasms Am. J. Pathol., January 1, 2000; 156(1): 21 - 27. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |